title: [New clinical concept and therapeutic strategy for TIA].
abstract: In the past, transient ischemic attack (TIA) was defined as any sudden, focal cerebral ischemic event with neurological deficit lasting <24 hours. However, in several series of patients with TIA who underwent diffusion-weighted magnetic resonance imaging, many ischemic episodes with symptoms lasting <24 hours are associated with new infarctions. Therefore, TIA working group proposed a new tissue-based, rather than a time-based, definition of TIA: "a brief episode of neurological dysfunction caused by a focal disturbance of brain or retinal ischemia, with clinical symptoms typically lasting less than 1 hour, and without evidence of infarction". The latest definition of TIA is "a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction". Recent studies have shown that stroke risk after TIA is high in the first few days. Two prognostic scores for short-term risk of stroke after TIA have been proposed: the California score and the ABCD score. The ABCD(2) score has the same components as ABCD, but with diabetes mellitus added. This score was a more accurate predictor than either of the previous scores. Antiplatelet therapy should be prescribed immediately for the secondary prevention of stroke in patients with a noncardioembolic TIA.
authors.affiliation: Department of Neurology, Juntendo University School of Medicine.
authors.forename: Takao
authors.initials: T
authors.lastname: Urabe
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage; D000077407:Cilostazol; D000077144:Clopidogrel; D038524:Diffusion Magnetic Resonance Imaging; D006801:Humans; D002546:Ischemic Attack, Transient / Q000150:complications / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D012306:Risk; D055502:Secondary Prevention; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013777:Tetrazoles / Q000008:administration & dosage; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D013997:Time Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077144:Clopidogrel; D000077407:Cilostazol; D013988:Ticlopidine; D001241:Aspirin